PonyWang Results from a phase 3 trial show that Merck's biologic Keytruda (pembrolizumab) + chemo improves overall survival as a neoadjuvant treatment followed alone as adjuvant therapy compared to pre-operative chemo alone in patients with high-risk, early-stage triple negative breast cancer. The drugmaker said an interim analysis from the phase 3 KEYNOTE-522 trial of the anti-PD-1 therapy conducted by an independent Data Monitoring Committee found that Keytruda led to a statistically significant improvement in overall survival compared to pre-operative chemotherapy. Merck (MRK) noted the data is the first to show that an immunotherapy-based regimen has a survival benefit compared to chemotherapy alone in those with high-risk, early-stage triple-negative breast cancer.
More on Merck Merck: The Worst Has Been Avoided (Rating Upgrade) Merck Q1: There's Still Room For Growth Merck, Kelun buoyed by phase 3 results for breast cancer antibody drug conjugate Merck HPV vaccine associated with lower head and neck cancer rates in men Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript).
